- Home
- LGCY vs MNOV Comparison
LGCY vs MNOV Comparison
Compare LGCY & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCY
- MNOV
- Stock Information
- Founded
- LGCY 2009
- MNOV 2000
- Country
- LGCY United States
- MNOV United States
- Employees
- LGCY N/A
- MNOV N/A
- Industry
- LGCY
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- LGCY
- MNOV Health Care
- Exchange
- LGCY NYSE
- MNOV Nasdaq
- Market Cap
- LGCY 87.3M
- MNOV 76.5M
- IPO Year
- LGCY 2024
- MNOV 2005
- Fundamental
- Price
- LGCY $7.17
- MNOV $1.47
- Analyst Decision
- LGCY Strong Buy
- MNOV Strong Buy
- Analyst Count
- LGCY 2
- MNOV 1
- Target Price
- LGCY $10.65
- MNOV $9.00
- AVG Volume (30 Days)
- LGCY 42.2K
- MNOV 9.6K
- Earning Date
- LGCY 05-15-2025
- MNOV 05-16-2025
- Dividend Yield
- LGCY N/A
- MNOV N/A
- EPS Growth
- LGCY 44.62
- MNOV N/A
- EPS
- LGCY 0.58
- MNOV N/A
- Revenue
- LGCY $52,722,310.00
- MNOV N/A
- Revenue This Year
- LGCY $33.77
- MNOV N/A
- Revenue Next Year
- LGCY $24.88
- MNOV N/A
- P/E Ratio
- LGCY $12.16
- MNOV N/A
- Revenue Growth
- LGCY 32.68
- MNOV N/A
- 52 Week Low
- LGCY $3.60
- MNOV $1.12
- 52 Week High
- LGCY $10.37
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- LGCY N/A
- MNOV 48.15
- Support Level
- LGCY N/A
- MNOV $1.46
- Resistance Level
- LGCY N/A
- MNOV $1.55
- Average True Range (ATR)
- LGCY 0.00
- MNOV 0.06
- MACD
- LGCY 0.00
- MNOV 0.00
- Stochastic Oscillator
- LGCY 0.00
- MNOV 25.00
About LGCY LEGACY EDUCATION INC
Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.